About Entrada Therapeutics
Entrada Therapeutics is a company based in Boston (United States) founded in 2016.. Entrada Therapeutics has raised $175.25 million across 2 funding rounds from investors including Goldman Sachs, Roche and Greenspring Associates. The company has 183 employees as of December 31, 2024. Entrada Therapeutics offers products and services including EEV Platform and Duchenne Program. Entrada Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Biogen and Rhythm Pharmaceuticals, among others.
- Headquarter Boston, United States
- Employees 183 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Entrada Therapeutics, Inc.
-
Annual Revenue
$210.78 M63.38as on Dec 31, 2024
-
Net Profit
$65.63 M1082.49as on Dec 31, 2024
-
EBITDA
$50.78 M15919.31as on Dec 31, 2024
-
Total Equity Funding
$175.25 M (USD)
in 2 rounds
-
Latest Funding Round
$116.25 M (USD), Series B
Mar 31, 2021
-
Investors
Goldman Sachs
& 12 more
-
Employee Count
183
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Entrada Therapeutics
Entrada Therapeutics is a publicly listed company on the NASDAQ with ticker symbol TRDA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Entrada Therapeutics
Entrada Therapeutics offers a comprehensive portfolio of products and services, including EEV Platform and Duchenne Program. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for delivering therapeutics to intracellular targets
Program developing treatments for Duchenne Muscular Dystrophy
Unlock access to complete
Unlock access to complete
Funding Insights of Entrada Therapeutics
Entrada Therapeutics has successfully raised a total of $175.25M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $116.25 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $116.2M
-
First Round
First Round
(22 Dec 2018)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series B - Entrada Therapeutics | Valuation | Wellington | |
| Dec, 2018 | Amount | Series A - Entrada Therapeutics | Valuation | 5AM Ventures , MPM Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Entrada Therapeutics
Entrada Therapeutics has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Goldman Sachs, Roche and Greenspring Associates. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment management firm
|
Founded Year | Domain | Location | |
|
Venture capital fund backed incubator focused on the healthcare startups
|
Founded Year | Domain | Location | |
|
Agent Capital is focused on healthcare venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Entrada Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Entrada Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Entrada Therapeutics Comparisons
Competitors of Entrada Therapeutics
Entrada Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Biogen and Rhythm Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Entrada Therapeutics
Frequently Asked Questions about Entrada Therapeutics
When was Entrada Therapeutics founded?
Entrada Therapeutics was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Where is Entrada Therapeutics located?
Entrada Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Who is the current CEO of Entrada Therapeutics?
Dipal Doshi is the current CEO of Entrada Therapeutics.
Is Entrada Therapeutics a funded company?
Entrada Therapeutics is a funded company, having raised a total of $175.25M across 2 funding rounds to date. The company's 1st funding round was a Series A of $59M, raised on Dec 22, 2018.
How many employees does Entrada Therapeutics have?
As of Dec 31, 2024, the latest employee count at Entrada Therapeutics is 183.
What is the annual revenue of Entrada Therapeutics?
Annual revenue of Entrada Therapeutics is $210.78M as on Dec 31, 2024.
What does Entrada Therapeutics do?
Entrada Therapeutics was founded in 2016 in Boston, United States, within the biotechnology sector focused on rare diseases. A proprietary intracellular biologics platform is utilized to enable delivery of proteins, peptides, and nucleic acids. The pipeline includes ENTR-601-44 for Duchenne Muscular Dystrophy and VX-670 for Myotonic Dystrophy Type 1, alongside candidates for immunology and ocular indications. Operations center on advancing these therapeutic options.
Who are the top competitors of Entrada Therapeutics?
Entrada Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Entrada Therapeutics offer?
Entrada Therapeutics offers EEV Platform and Duchenne Program.
Is Entrada Therapeutics publicly traded?
Yes, Entrada Therapeutics is publicly traded on NASDAQ under the ticker symbol TRDA.
Who are Entrada Therapeutics's investors?
Entrada Therapeutics has 13 investors. Key investors include Goldman Sachs, Roche, Greenspring Associates, Wellington, and Redmile Group.
What is Entrada Therapeutics's ticker symbol?
The ticker symbol of Entrada Therapeutics is TRDA on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.